Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2010

View Archived Issues

alpha2A-Adrenoceptor gene polymorphism and overexpression linked to type 2 diabetes

Prostanoid DP receptor antagonist AMG-853 safe in humans

Bepreve reduces allergen-induced ocular itching, nasal congestion and rhinorrhea in phase III trials

XF-73 and XF-70 active against pathogens relevant to biodefense

Submicron budesonide formulation may innovate pediatric asthma treatment

Vaccination with autologous HIV-1-pulsed DCs feasible in HIV

Janssen presents novel dopamine and serotonin receptor antagonists

Sanofi-aventis claims new cannabinoid CB1 receptor antagonists

Boehringer Ingelheim claims novel EGFR inhibitors

Nabi stockholders approve NicVAX option and license agreement

Capstone continues phase II trial of AZX-100 in keloid scarring

Bristol-Myers Squibb and Allergan enter global agreement on ExonHit's AGN-209323

Final dose level approved in Pluristem's phase I trial of PLX-PAD

Seattle Genetics achieves milestone under antibody-drug conjugate collaboration with Genentech

Enanta nominates EDP-239 as lead development candidate for HCV

FDA approves Novo Nordisk's Norditropin FlexPro prefilled growth hormone pen

NicOx grants Bausch & Lomb worldwide rights to NCX-116

Lilly and Transition Therapeutics enter into licensing and collaboration agreement

Solasia and Kyowa Hakko Kirin license agreement for SP-01 in Asia

Lundbeck and Takeda plan phase III trials of Lu-AA21004 and Lu-AA24530

Pfizer and Medivation report phase III results on Dimebon in Alzheimer's disease

Genzyme and PTC report on phase IIb ataluren trial in nmDBMD

Chiesi identifies novel muscarinic M3 receptor antagonists

Light Sciences Oncology completes enrollment in phase III Aptocine trial in MCRC

Advanced Cell Technology's RPE cells granted FDA orphan drug status / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...